Microbot Medical Inc. (NASDAQ: MBOT) has announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR) titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study." This study, led by Dr. Francois Cornelis, the Lead Principal Investigator for the LIBERTY ACCESS PVI Pivotal Study, highlights the innovative capabilities of Microbot's LIBERTY Endovascular Robotic System. The publication in a prestigious peer-reviewed journal underscores the quality and impact of the research conducted, which is expected to bolster the company's position in the market for endovascular procedures. The LIBERTY system, which received FDA clearance in September 2025, is designed to enhance precision and reduce radiation exposure during vascular navigation. The company aims to leverage this publication to expand evidence-based data supporting broader commercial adoption of the LIBERTY system, with plans for a full market release at the upcoming Society of Interventional Radiology (SIR) conference in April 2026. This strategic move is anticipated to enhance Microbot's visibility and credibility within the medical community, potentially leading to increased adoption and sales of the LIBERTY system.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.